Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

KAYNAR L., Coppo P., Scully M., LaRubia J., Peyvandi F., Cataland S., ...More

XIth Eurasian Hematology Oncology, 21 - 24 October 2020, vol.42, pp.62-63

  • Publication Type: Conference Paper / Full Text
  • Volume: 42
  • Doi Number: 10.1016/j.htct.2020.09.112
  • Page Numbers: pp.62-63
  • Erciyes University Affiliated: Yes